← Open Payments lookup

THOMAS VALENTE: Open Payments

NPI 1467416511 · LEESBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$270,227 in 435 payments from 18 companies in 2025. Trend: 2023 $188,365 · 2024 $156,480 · 2025 $270,227

Speaker / faculty: $210,171Consulting: $31,690Travel & lodging: $13,333Food & beverage: $10,634Honoraria: $4,400
CompanyPaymentsAmount
Neurocrine BioSciences, Inc.104$71,655
E.R. Squibb & Sons, L.L.C.82$56,308
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)73$48,134
Otsuka America Pharmaceutical, Inc.44$35,251
Teva Pharmaceuticals USA, Inc.43$27,365
Alkermes, Inc.29$11,134
Boehringer Ingelheim Pharmaceuticals, Inc.12$8,348
Otsuka Pharmaceutical Development & Commercialization, Inc.7$5,420
Luye Pharma (USA) Ltd.10$4,402
Janssen Pharmaceuticals, Inc7$1,480

Products named: INGREZZA, COBENFY, CAPLYTA, REXULTI, AUSTEDO XR, ABILIFY MAINTENA, UZEDY, LYBALVI.

Industry payments across FL — which companies pay providers there.